 - Subjects without EGFR activating mutation or ALK translocation. Subjects with EGFR activating mutation or ALK translocation are eligible only after failing TKI therapy such as gefitinib, erlotinib, or afatinib. Furthermore, if a T790M resistance mutation is found, the patient must have failed a 3rd generation TKI such as osimertinib. 